Christian O. Henry Sells 10,500 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Christian O. Henry sold 10,500 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Wave Life Sciences Trading Down 0.8 %

WVE opened at $9.59 on Friday. The stock’s 50-day moving average price is $10.92 and its 200 day moving average price is $11.55. Wave Life Sciences Ltd. has a 12-month low of $4.25 and a 12-month high of $16.74. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -8.64 and a beta of -1.04.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.34. The company had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, research analysts forecast that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Wave Life Sciences

A number of hedge funds have recently bought and sold shares of WVE. GF Fund Management CO. LTD. acquired a new stake in Wave Life Sciences in the 4th quarter valued at about $40,000. Quarry LP acquired a new stake in Wave Life Sciences in the 4th quarter valued at about $62,000. KBC Group NV acquired a new stake in Wave Life Sciences in the 4th quarter valued at about $67,000. Point72 DIFC Ltd acquired a new stake in Wave Life Sciences in the 3rd quarter valued at about $98,000. Finally, Summit Investment Advisors Inc. raised its position in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after purchasing an additional 2,308 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on WVE shares. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, March 5th. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target for the company. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Wave Life Sciences currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.